000 04147nam a22003855i 4500
001 282878
003 MX-SnUAN
005 20160429154210.0
007 cr nn 008mamaa
008 150903s2008 ne | o |||| 0|eng d
020 _a9781402086960
_99781402086960
024 7 _a10.1007/9781402086960
_2doi
035 _avtls000336110
039 9 _a201509030257
_bVLOAD
_c201404300311
_dVLOAD
_y201402041341
_zstaff
040 _aMX-SnUAN
_bspa
_cMX-SnUAN
_erda
050 4 _aRC261-271
100 1 _aStigbrand, Torgny.
_eeditor.
_9309969
245 1 0 _aTargeted Radionuclide Tumor Therapy :
_bBiological Aspects /
_cedited by Torgny Stigbrand, Jörgen Carlsson, Gregory P. Adams.
264 1 _aDordrecht :
_bSpringer Netherlands,
_c2008.
300 _brecurso en línea.
336 _atexto
_btxt
_2rdacontent
337 _acomputadora
_bc
_2rdamedia
338 _arecurso en línea
_bcr
_2rdacarrier
347 _aarchivo de texto
_bPDF
_2rda
500 _aSpringer eBooks
505 0 _ato Radionuclide Therapy -- Therapeutically Used Targeted Antigens in Radioimmunotherapy -- EGFR-Family Expression and Implications for Targeted Radionuclide Therapy -- Targeting Tumours with Radiolabeled Antibodies -- Antibody Fragments Produced by Recombinant and Proteolytic Methods -- Novel Alternative Scaffolds and Their Potential Use for Tumor Targeted Radionuclide Therapy -- Peptides for Radionuclide Therapy -- Choice of Radionuclides and Radiolabelling Techniques -- High-LET-Emitting Radionuclides for Cancer Therapy -- Targeted High-LET Therapy of Bone Metastases -- The Auger Effect in Molecular Targeting Therapy -- Radiation Induced Cell Deaths -- Radiation Induced DNA-Damage/Repair and Associated Signaling Pathways -- Radiation Induced DNA Damage Checkpoints -- Cancer Stem Cells and Radiation -- Effects of Low Dose-Rate Radiation on Cellular Survival -- Bystander Effects and Radionuclide Therapy -- Enhancing the Efficiency of Targeted Radionuclide Therapy -- Low Dose Hyper-Radiosensitivity: A Historical Perspective -- Clinical Radionuclide Therapy -- Developmental Trends in Targeted Radionuclide Therapy: Biological Aspects.
520 _aThe last three decades have provided opportunities to explore the potential of treating malignant diseases with antibodies or other targeting molecules labelled with nuclides. The expanding array of new targeting molecules (recombinant antibodies or peptides) may increase the therapeutic efficacy. The title of this book "Targeted Radionuclide Tumor Therapy – Biological aspects" was selected to reinforce the concept that a major focus was devoted to understanding the biological effects of targeting and radiation. Furthermore, our rapidly expanding knowledge of low dose-rate effects, different types of cell death, autosensitization and the increasingly likely existence of cancer stem cells suggests to us that even more efficient approaches in targeting might be possible in the future. The development of targeted therapy is a true multidisciplinary enterprise involving physician scientists from the fields of nuclear medicine, radiation therapy, diagnostic radiology, surgery, gynaecology, pathology and medical oncology/haematology. It also involves many preclinical scientists working with experimental animal models, immunochemistry, recombinant antibody technologies, radiochemistry, radiation physics and basic cell biology. It is the ambition of the editors to enable deeper insights in the process of improving targeted therapy. We believe that the time now has come when targeted therapy can soon be added to standard oncology treatment regimens.
590 _aPara consulta fuera de la UANL se requiere clave de acceso remoto.
700 1 _aCarlsson, Jörgen.
_eeditor.
_9309970
700 1 _aAdams, Gregory P.
_eeditor.
_9309971
710 2 _aSpringerLink (Servicio en línea)
_9299170
776 0 8 _iEdición impresa:
_z9781402086953
856 4 0 _uhttp://remoto.dgb.uanl.mx/login?url=http://dx.doi.org/10.1007/978-1-4020-8696-0
_zConectar a Springer E-Books (Para consulta externa se requiere previa autentificación en Biblioteca Digital UANL)
942 _c14
999 _c282878
_d282878